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INTRODUCTION
Nonconventional knee endoprostheses are largely employed in 
reconstructions after bone tumor resections around the knee. This 
kind of implant presents the same complication rates as the con-
ventional knee prostheses. 
The name ‘nonconventional endoprosthesis’ is due to the fact that 
the osteotomy for its placement is more extensive than in the cases 
of conventional prostheses. In conventional knee prostheses, os-
teotomy reaches the distal metaphyses of the femur and proximal 
metaphyses of the tibia, being usually performed with the aid of 
metaphyseal templates. On the other hand, in nonconventional 
endoprostheses, there is no rule of thumb for the osteotomy loca-
tion. Bone resection varies according to the size of the tumor and 
the oncologic margin of the lesion. 
The bone affected by tumor, in the large majority of times, is submit-
ted to a diaphyseal osteotomy. This kind of diaphyseal resection 
gives rise to a large bone failure, requiring the use of an implant 
enabling bone length and its perfect joint alignment reestablish-
ment. Nonconventional endoprostheses were introduced, thus, 
as a method for reconstructing bone failures resulting from the 
resection of musculoskeletal tumors.1-4
The major acute complications of this kind of surgery are infection, 
dehiscence, collections formation, such as hematoma or seroma 
and deep venous thrombosis.3,5 At late stages, this kind of proce-
dure may present other complications, such as aseptic loosening 
of the implant, a broken component of the endoprosthesis, peri-
prosthetic infection, and septic loosening of the implant. In addi-
tion to those, local recurrence of tumor may occur, with or without 
implant loosening.4,6
Peri-prosthetic infections are usually symptomatic. The classical 
signs of local heat, redness, and pain may be present. Fistuliza-
tion of collections is a common event in these cases, with serous, 
blood red cells or purulent leakage. In some cases of late infection 
we didn’t find at first any classical inflammatory signs. The patient 
may evolve with pain at prosthesis site and, at the X-ray evaluation, 
signs of components loosening can be visualized or not.7 These 
cases constitute a greater challenge for diagnosis.
The key laboratory changes are the leukogram modification (with 
an infectious pattern), increased hemosedimentation speed and 
increased serum reactive C protein. These tests, in addition to 
support the diagnosis, serve as parameters of the therapeutic 
response during patient’s follow-up. On X-ray tests, we can find 
endoprosthesis loosening (lysis around the cement) and deep peri-
prosthetic collections.
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ABSTRACT
Objective: The aim of this study is to evaluate the use of cement 
spacers impregnated with antibiotics for the treatment of infections 
in the nonconventional endoprostheses of the knee. Methodology: 
We have treated seven patients since 2004 (of which six were sub-
mitted to surgery in our service and one patient had been submitted 
to a primary tumor surgery in another removal service) with deep 
infection in knee tumor prosthesis. All patients were submitted to 
endoprosthesis removal and reconstructed with antibiotic cement 
spacer. All patients were monitored both clinically and by lab tests as 
for monitoring the evolution, being considered able for reviews after 6 
(six) months without infections signs. Results: We have noted a small 
predominance of infectious processes on the prosthesis inserted on 
proximal tibia as compared with distal femur (57.1% x 42.9%). The 
mean follow-up time of patients was 68.2 months. During the follow 
up, one patient died as a result of the root disease. Six patients out 
of seven were regarded as cured and one persisted with infection 
signs and symptoms. Conclusion: The results obtained up to date 
have motivated us to continue using this method of treatment.
Keywords: Prosthesis. Neoplasms. Infection. Bone cements. 
Osteosarcoma.
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The classical treatment for peri-prosthetic infections relies on 
therapy with antibiotics driven by results of cultures and antibio-
grams and by the removal of the infected endoprosthesis. In cases 
of infection around nonconventional endoprostheses, the bone 
failure found after the implant removal requires a reconstruction 
method. 
Many authors recommended amputation as a definitive method 
for fixing infections around knee endoprostheses.8 Reconstruction 
techniques are based on joint arthrodesis after bone transportation 
with the method by Ilizarov. Another technique fosters transporta-
tion with the use of linear fixators and subsequent arthrodesis. 
Arthrodesis in situ may also be provided, causing a dramatic short-
ening the limb. In this case, there is no bone transportation, and 
the limb becomes quite shorter. 
Following the same treatment approach as in peri-prosthetic infec-
tions for knee total arthroplasty, the use of acrylic cement spacers 
with antibiotics was suggested. In this treatment approach, the 
spacer provides, in addition to its mechanical function, a thera-
peutic antibacterial function, with the local release of antibiotic 
agents.
Since the bone failure found after UCE removal is quite large, using 
a cement spacer only is not enough for providing an appropriate 
mechanical stabilization. With the purpose of improving mechani-
cal stabilization, the technique using a cement spacer with a stiff 
nail inside it was developed. Thus, the cement with antibiotics 
makes contact with bone and muscular bed, and the nail at the 
assembly core allows a better functional stabilization.
Once the spacer system is assembled, the patient is clinically 
treated (for a variable period of time) with appropriate antibiotics 
(based on culture and antibiogram results of materials collected at 
the peri-prosthetic region), and, after total remission of signs and 
symptoms, and upon the stabilization of laboratory parameters, 
the spacer can be removed and replaced by a new NCE.9,10
The objective of this study is to present a method for treating 
deep infections in patients submitted to tumoral resection and 
reconstruction with nonconventional knee endoprosthesis. 
MATERIALS AND METHODS
Between January 1st, 1990 and December 31st, 2006, 283 surger-
ies for inserting an nonconventional knee endoprosthesis after tu-
moral resection (patients with tumors on distal femur and proximal 
tibia) have been carried out in our service.
During follow-up, 24 (twenty-four patients – 8.48%) patients 
evolved with deep infection of the endoprosthesis site. Up to 
2004, the patients with deep peri-prosthetic infection were treat-
ed by removing the endoprosthesis and with external fixation 
(for elongation or arthrodesis) or with amputation of the limb. 
From 2004 on, we started to operate the patients by removing 
the endoprosthesis followed by reconstruction with acrylic ce-
ment spacer with antibiotics. The case series of this study, thus, 
consists of 6 (six) patients with peri-prosthetic infection operated 
from 2004 on, added by a patient submitted to tumoral resection 
surgery and reconstruction with nonconventional endoprosthesis 
whose surgery was performed in another hospital, being subse-
quently followed up in our outpatient service. When this patient 
was referred to our outpatient facility, he already presented with 
deep infection, making use of oral antibiotics for 3 months, and 
he had already been submitted to surgical debridement on the 
endoprosthesis site.
The studied patients, as approved by UNIFESP/EPM’s Committee 
of Ethics, consisted of 2 males (28,6%) and 5 females (71.4%). 
The mean age when the infection was diagnosed was 35.9 years 
(range: 11-68 years). Concerning the baseline disease, 6 (six) 
patients had osteosarcoma (3 metastatic and 3 non-metastatic), 
and 1 patient presented giant cells tumor (GCT) as a baseline 
pathology. The six patients affected by osteosarcoma were sub-
mitted to a neo-adjuvant and adjuvant chemotherapy approach 
(according to the protocol in force at the moment of diagnosis). 
The patient with GCT had a tumor on distal femur with extra-bony 
lesion, showing resection with wide margins and reconstruction 
with nonconventional knee prosthesis. This patient had 2 episodes 
of local recurrence, and he was submitted to resection of the recur-
rences around the prosthesis. No patient received radiotherapy 
as adjuvant treatment.
All patients received therapy with antibiotics (oral and endovenous) 
when diagnosed with infection. During follow-up, all patients were 
submitted to at least one surgical debridement surgery but not 
removing prosthesis components. All patients were followed up 
through leukograms, hemosedimentation speed and reactive C 
protein tests. All patients received therapy with specific antibiotics 
after culture tests and antibiograms collected intraoperatively at 
debridement procedure.
All patients with persistent infection after one surgical debridement 
event and receiving antibiotic therapy for at least 6 weeks (specific 
antibiotic therapy) were regarded as eligible for endoprosthesis 
removal and limb reconstruction with modeled spacers with nail 
and cement with antibiotics. In our case series, all patients with 
infection after 2004 were regarded as eligible to treatment.
The seven patients were submitted to a new surgical procedure 
through the same port used for tumor resection. In cases where 
fistulas were present, fistulectomy was carried out with resection of 
the whole scar (ellipse resection). By performing the endoprosthe-
sis approach, new culture and antibiogram samples were collected 
in order to guide the postoperative antibiotic therapy approach. The 
endoprostheses were removed (all the components) and all the 
cement previously used was removed. We performed an extensive 
debridement of the necrotic tissues around the endoprosthesis. 
At the bone approach, a careful curettage of the femoral and 
tibial medullar was performed. After the debridement, the area 
was cleaned with saline solution 0.9% (at least 15 liters were used 
in each procedure).
For reconstruction, femoral nails were used wrapped with cement 
with antibiotics. In all patients, the Simplex® brand acrylic cement 
with antibiotics (Tobramycin) was used.
In order to determine infection control, we employed clinical and 
laboratory parameters. Clinically, we saw total healing of the sur-
gical wound, absence of fistulas and leakages, and absence of 
flogistic signs. Concerning laboratory analysis, we saw the reduc-
tion of Hemosedimentation speed, reactive C protein, and leuko-
gram levels to normal parameters. We regarded a patient as able 
to endoprosthesis replacement when the clinical and laboratory 
parameters remained   at normal levels for 6 (six) months (Figures 
1 and 2).
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Figure 1 -  Acrylic cement spacer with antibiotics around a metal nail (single 
nail).
Figure 2 - Acrylic cement spacer with antibiotics around a metal nail (double 
nail).
Figure 3 – Evolution time (days) between the endoprosthesis insertion and the 
onset of infection according to the number of cases.
Figure 4 – Signs and symptoms of the infectious picture of patients by 
frequency order.
RESULTS
We found a subtle prevalence of the incidence of infectious pro-
cess on prosthesis implanted in patients with proximal tibial tumors 
when compared to the baseline location of the tumor on the distal 
femur (57.1% of the cases showed a baseline tumor on proximal 
tibia, while 42.9% on the distal femur). 
Concerning the endoprosthesis model employed, in 6 patients an 
nonconventional custom-made prosthesis was used, and, in one 
case, this was an extensible-type endoprosthesis. This was the only 
patient in the case series presenting with a partial knee prosthesis 
(only the femoral component). The size of the endoprosthesis body 
was, in average, 142.9 mm.
Concerning the anatomical-pathological report, all patients were sub-
mitted to resections with wide margins and presented free margins.
The patients presented the first signs and symptoms correspond-
ing to infectious processes within a period that ranged from 3 
to 127 months after the endoprosthesis insertion surgery (mean: 
32.1 months, and median: 24.8 months (Figure 3)). The signs 
and symptoms found in our study were the following: pain (n=6, 
85.7% of the patients), active fistula (n=5, 71.4% of the patients), 
local heat (n=3, 42.9% of the patients), redness (n=3, 42.9% of 
the patients), palpable liquid collection (n=2, 28.6% of the pa-
tients), skin lesion and prosthesis exposure (n=2, 28.6% of the 
patients) and diffuse edema on the limb (n=1, 14.3% of the pa-
tients). (Figure 4)
All patients were submitted to at least one surgical procedure for 
debridement and surgical cleaning previously to the indication of 
endoprosthesis removal. One patient (the one diagnosed with gi-
ant cell tumor) was submitted to two surgical cleaning procedures 
previously to the indication of endoprosthesis removal.
The time elapsed between clinical diagnosis of infection and en-
doprosthesis removal ranged from 2.3 months and 88.8 months 
(mean: 35.2 months, and median: 12.1 months). The time elapsed 
between the 1st surgery and the endoprosthesis removal ranged 
from 13.3 months to 129.3 months (mean: 67; median: 69.6 
months).
Acrylic cement spacers with antibiotics may be placed for blocking 
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Figure 5 – Correlation between time for remission of the clinical picture and 
inflammatory signs.
knee joint (single nail) or with two nails (assembling 2 separate 
spacers, one for the femur and another for the tibia), allowing 
a pseudoarticulation between spacers (double nail). In the case 
series presented here, 2 (two) (28.6%) double-nail spacers, and 5 
(five) (71.4%) single-nail spacers were inserted. All spacers were 
assembled with Simplex® cement with Tobramycin. 
For the screening of etiologic agents, cultures were collected in-
traoperativelly from the endoprostheses beds. The identified etio-
logic agents were the following: Staphylococcus aureus in 4 cases 
(57.1%), Acinetobacter in 1 case (14.3%), Streptococcus sp. in 1 
case (14.3%), and Enterobacter in 1 case (14.3%). All patients 
received postoperative therapy with specific antibiotics according 
to the culture and the antibiogram. Thus, 4 patients (57.1%) were 
treated with ciprofloxacin, 2 patients (28.6%) were treated with 
vancomycin, and 1 patient (14.3%) was treated with sultamycin. 
Antibiotic therapy time ranged from 2 to 33 months (mean: 5.5 
months) after endoprosthesis removal.
The most prevalent objective clinical sign is the presence of active 
fistula. Additionally to the fistula, classical inflammatory signs were 
assessed (heat, redness, edema and pain), as well as laboratory 
parameters. (Figure 5). Of the 7 patients assessed, 6 (85.7% of the 
cases) evolved with clinical and laboratory parameters improve-
ment, while one patient didn’t present improvement and evolved 
with persistent infectious process.
For the 6 patients responding well to the recommended treatment, 
the mean time for fistulas closing was 4 weeks (3-24 weeks). In-
flammatory signs have also improved, returning to normal levels 
within 4 weeks (3-24 weeks), while the mean time for HSS and 
reactive C protein normalization was 20 weeks (12-100 weeks). 
(Figure 5)
The mean follow-up time is 68.2 months (13.9 to 120.9 months). 
One patient was submitted to spacer removal and endoprosthesis 
replacement. Currently, this patient shows no signs of infection 
on the new endoprosthesis. Concerning the other 6 patients, one 
is waiting for endoprosthesis replacement, one died as a result 
of the baseline disease, and the remaining 4 did not accept to 
be submitted to a new surgical procedure at risk of perpetuating 
the infectious process. These patients remained with the spacers, 
and no major complication was found so far.
Of the 7 (seven) patients submitted to spacer insertion, 6 (six) 
evolved with shortening of the affected limb, which ranged from 
1.5 to 8 cm (mean: 3.2 cm).
Taking only the patients who survived throughout follow-up into ac-
count, we have a cure rate of 83.3% with the described method. 
Due to the small sample, we couldn’t design an appropriate mul-
tifactorial analysis to determine which variables present a stronger 
impact for peri-endoprosthetic infection treatment.
DISCUSSION
Infection is one of the most feared complications occurring in 
orthopaedic surgeries. Tumor resection surgery and the reconstruc-
tion with NCE present a risk of infection ranging from 5% to 35%. 
Such high incidence occurs mainly because of oncologic patients’ 
characteristics, which, many times, have diseases leading to immu-
nosupression. Furthermore, chemotherapy and radiotherapy play 
an immunosuppressant role (both local and systemic), increasing 
the risks of infection.
On the other hand, tumor resection surgeries requiring reconstruc-
tion with NCE are major procedures, showing a lengthy surgical 
time and leading to a higher risk of infections.
Since the 1970’s, many authors have tried to determine which 
would be the best method for peri-prosthetic infection treatment. 
The first treatment method described for treating infections in knee 
total arthroplasties was the plain surgical cleaning, recommended 
to any type of infection around implant materials.11 Brodersen et 
al.12 were the first to describe, in the 1970’s, knee arthrodesis as 
a method for treating arthroplasty failures. In their series of 45 pa-
tients, 40 presented infection as the root cause of implant failure, 
being submitted to knee arthrodesis.
Phillips et al.13 have also proposed knee arthrodesis after an im-
plant removal, but using the Hoffman’s external fixator. With this 
technique, they were able to achieve a faster union and less short-
ening compared to internal techniques.
Insall14 was the first author to write a review article about the 
peri-prosthetic infections theme. The author considered surgical 
cleaning as imperative, as well as the implant removal and en-
dovenous antibiotic therapy. Insall was also the first to suggest 
the review in two steps. After the surgery, the patient would be 
on endovenous antibiotic therapy for six weeks, and only after 
that period a new surgery for inserting the new prosthesis would 
be indicated.
Poss et al.15, in the 1980’s, assessed 4240 patients in an attempt 
to determine which would be the most important groups at risk of 
infection around the knee. In their text, the authors discuss that the 
pathologies leading to immunosuppression are the key risk factor 
for infection around knee total arthroplasty, followed by patients 
with previous review procedures. Bliss and McBride16 emphasized, 
at the time, the importance of the full prosthesis coverage with 
myocutaneous flaps.
In the 1980’s, Borden and Gearen17 suggested a treatment protocol 
for knee total peri-prosthesis infection. The methods described 
by the authors consisted of primary review of the prosthesis, ag-
gressive and isolated surgical cleaning, and of the review in two 
steps.
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Wilde and Ruth18 pioneered the description of a review method in 
two steps with the use of an acrylic cement spacer with antibiotics. 
In that initial study, the authors removed the prosthesis and kept 
the patient under endovenous antibiotic therapy for 4.2 weeks, 
and removing the spacer and replacing arthroplasty. Morrey et 
al.19, in 1989, recommended that, in acute infections, aggressive 
debridement and surgical cleaning should be made, which could 
cure the infection in up to 80% of the cases.
Wirganowicz et al.3 assessed the causes of nonconventional 
endoprosthesis failures. The authors assessed 278 prostheses, 
finding an infection rate of 13%. More recently, Gosheger et al.20 
assessed the effects of a silver layer on the endoprosthesis as 
a way to reduce the rate of infections. In an experimental study, 
the authors concluded that silver could reduce the risk of peri-
prosthetic infection from 47% (control group) to 7%.
Since literature does not describe which would be the best method 
for treating deep infections around nonconventional knee endo-
prostheses, we found support on treatment techniques for infec-
tions around knee total arthroplasties. Our primary concern was 
maintaining a conservative surgery on the limb. The indication 
of surgical cleaning previously to the endoprosthesis removal is 
described, which can lead to resolution of the infectious process 
without requiring a more aggressive procedure.
CONCLUSION
Based on our findings, we couldn’t determine the key positive 
predictive factors for a better evolution in cases of infection around 
nonconventional endoprostheses. However, we conclude that the 
method employed shows good results with great chances of curing 
the infectious process.
We also conclude that the major complication resulting from the 
method is dysmetria of the affected limb.
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